2024
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine
Zeidan A, Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Halene S, Haferlach T, Fox B. Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic Advances In Hematology 2024, 15: 20406207241257904. PMID: 38883163, PMCID: PMC11180421, DOI: 10.1177/20406207241257904.Peer-Reviewed Original ResearchHigher-risk myelodysplastic syndromesAcute myeloid leukemiaBone marrowMutation statusImmune landscapeImmunological landscapeAnti-PD-L1 antibody durvalumabHR-MDS patientsWild-type acute myeloid leukemiaTP53-mutant acute myeloid leukemiaMutant acute myeloid leukemiaAzacitidine-based therapyWild-type patientsImmune checkpoint proteinsImmune checkpoint expressionT cell populationsWild-typeStatistically significant decreaseAZA therapyImmunosuppressive microenvironmentPD-L1Mutant patientsDNA methylation arraysCheckpoint expressionMyelodysplastic syndrome
2022
MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program
Zeidan A, Al-Kali A, Borate U, Cluzeau T, DeZern A, Esteve J, Giagounidis A, Kobata K, Lyons R, Platzbecker U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma F, Iordan A, Sabo J, Garcia-Manero G. MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s317. DOI: 10.1016/s2152-2650(22)01420-3.Peer-Reviewed Original ResearchHematopoietic stem cell transplantLeukemia-free survivalPhase II trialHigh-risk myelodysplastic syndromeHR-MDS patientsClinical trial programII trialLeukemic stem cellsCombination therapyTim-3Trial programLeukemic cellsTransfusion-free intervalEvent-free survivalPhase III trialsStem cell transplantOverall response rateEarly phase trialsNovartis Pharmaceuticals CorporationImprovement of fatigueExpansion cohortIntensive chemotherapyPrimary endpointDurable responsesIII trials
2020
The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents
Joshi N, Kale H, Corman S, Hill K, Wert T, Zeidan A. The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents. Blood 2020, 136: 17-18. DOI: 10.1182/blood-2020-139642.Peer-Reviewed Original ResearchNon-persistent groupHealthcare resource useDirect medical costsHigh-risk myelodysplastic syndrome (MDS) patientsHR-MDS patientsNon-persistent patientsMyelodysplastic syndrome patientsHMA treatmentCurrent equity holderMedical costsHR-MDSPersistent patientsSyndrome patientsPropensity score-based inverse probabilityContinuous Medicare enrollmentTotal PPPM costsEnd Results-MedicareStem cell transplantRetrospective cohort designHealthcare spendingLoss of responseSubstantial cost burdenHospice care useCurrent employmentER costs
2018
Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)
Zeidner J, Knaus H, Zeidan A, Blackford A, Montiel-Esparza R, Prince G, Gondek L, Ghiaur G, Showel M, DeZern A, Pratz K, Smith B, Levis M, Foster M, Coombs C, Streicher H, Karp J, Luznik L, Gojo I. Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS). Blood 2018, 132: 335. DOI: 10.1182/blood-2018-99-114961.Peer-Reviewed Original ResearchEarly lymphocyte recoveryTimed sequential therapyAcute myeloid leukemiaMinimal residual diseaseT cellsLymphocyte recoveryCR rateMedian timeDay 1Phase 1 dose-escalation studyALT/AST elevationsAcute respiratory distress syndromeSecondary acute myeloid leukemiaAdverse-risk cytogeneticsHR-MDS patientsNon-hematologic gradePoor-risk subsetStandard induction therapyAcute kidney injuryMedian overall survivalPeripheral blood CD4Disease-free survivalDose-escalation studyEvent-free survivalGrade 3 rash
2015
Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2015, 126: 3285. DOI: 10.1182/blood.v126.23.3285.3285.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeHR-MDS patientsKaplan-Meier survival curvesEnd of studyHMA initiationMedian OSClinical trialsComorbidity countHazard ratioHigh school educationClinical practiceMultivariate Cox proportional hazards modelSurvival curvesEnd Results-Medicare databaseMedian household incomeRandomized phase III trialReal-world clinical practiceCox proportional hazards modelOlder MDS patientsDisability Status ScoreRetrospective cohort studyOverall survival advantagePhase III trialsYear of diagnosisErythropoiesis-stimulating agents
2013
The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)
Zeidan A, Al Ali N, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette P, Lancet J, List A, Komrokji R. The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza). Blood 2013, 122: 2771. DOI: 10.1182/blood.v122.21.2771.2771.Peer-Reviewed Original ResearchMD Anderson Prognostic Scoring SystemMedian overall survivalHigh-risk groupMoffitt Cancer CenterAZA therapyHR-MDSOverall survivalPrognostic scoring systemMyelodysplastic syndromeIntermediate riskRisk groupsLower riskScoring systemPrognostic groupsInt-2Therapy-related myelodysplastic syndromeHigh-risk myelodysplastic syndromeCycles of therapyHR-MDS patientsKaplan-Meier curvesLog-rank testOff-label useAZA initiationRevised IPSSR-IPSS